<DOC>
	<DOC>NCT02710604</DOC>
	<brief_summary>This is a phase 2a study to evaluate the safety and tolerability of multiple oral doses of CMX157 at increasing dose levels.</brief_summary>
	<brief_title>Phase 2, Multiple Ascending Dose Proof of Concept Study</brief_title>
	<detailed_description>This is a phase 2a study to evaluate the safety and tolerability of multiple oral doses of CMX157 at increasing dose levels in hepatitis B virus(HBV) infected subjects.</detailed_description>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Capable of giving written informed consent. Capable of completing study requirements. Chronic hepatitis B positive. HBV treatment na√Øve. Positive result for HCV(hepatitis C virus), HDV(hepatitis D virus) or HIV(human immunodeficiency virus). History or medical condition that could impact patient safety. Current or past abuse of alcohol or illicit drugs. Abnormal laboratory value or ECG. Pregnant or breastfeeding. Clinical, histologic or laboratory evidence of significant liver fibrosis or cirrhosis. Systemic immunosuppression. Received an investigational drug or investigational vaccine within the 90 days prior to the first dose of study drug.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>chronic hepatitis B(CHB)</keyword>
</DOC>